<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:57:25Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4502439" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4502439</identifier><datestamp>2015-07-21</datestamp><setSpec>elsevierwt</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neuromuscul Disord</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neuromuscul. Disord</journal-id>
      <journal-title-group>
        <journal-title>Neuromuscular Disorders</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0960-8966</issn>
      <issn pub-type="epub">1873-2364</issn>
      <publisher>
        <publisher-name>Pergamon Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4502439</article-id>
      <article-id pub-id-type="pmcid">PMC4502439</article-id>
      <article-id pub-id-type="pmc-uid">4502439</article-id>
      <article-id pub-id-type="pmid">25891276</article-id>
      <article-id pub-id-type="publisher-id">S0960-8966(15)00106-6</article-id>
      <article-id pub-id-type="doi">10.1016/j.nmd.2015.03.011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with <italic>ANO5</italic> mutations</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Savarese</surname>
            <given-names>Marco</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">a</xref>
          <xref rid="af0015" ref-type="aff">b</xref>
          <xref rid="fn0010" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Di Fruscio</surname>
            <given-names>Giuseppina</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">a</xref>
          <xref rid="af0015" ref-type="aff">b</xref>
          <xref rid="fn0010" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tasca</surname>
            <given-names>Giorgio</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruggiero</surname>
            <given-names>Lucia</given-names>
          </name>
          <xref rid="af0025" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Janssens</surname>
            <given-names>Sandra</given-names>
          </name>
          <xref rid="af0030" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Bleecker</surname>
            <given-names>Jan</given-names>
          </name>
          <xref rid="af0035" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Delpech</surname>
            <given-names>Marc</given-names>
          </name>
          <xref rid="af0040" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Musumeci</surname>
            <given-names>Olimpia</given-names>
          </name>
          <xref rid="af0045" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Toscano</surname>
            <given-names>Antonio</given-names>
          </name>
          <xref rid="af0045" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Angelini</surname>
            <given-names>Corrado</given-names>
          </name>
          <xref rid="af0050" ref-type="aff">i</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sacconi</surname>
            <given-names>Sabrina</given-names>
          </name>
          <xref rid="af0055" ref-type="aff">j</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santoro</surname>
            <given-names>Lucio</given-names>
          </name>
          <xref rid="af0025" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ricci</surname>
            <given-names>Enzo</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Claes</surname>
            <given-names>Kathleen</given-names>
          </name>
          <xref rid="af0030" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Politano</surname>
            <given-names>Luisa</given-names>
          </name>
          <xref rid="af0060" ref-type="aff">k</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nigro</surname>
            <given-names>Vincenzo</given-names>
          </name>
          <email>vinnigro@gmail.com</email>
          <email>vincenzo.nigro@unina2.it</email>
          <xref rid="af0010" ref-type="aff">a</xref>
          <xref rid="af0015" ref-type="aff">b</xref>
          <xref rid="co0010" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af0010"><label>a</label>Telethon Institute of Genetics and Medicine, Pozzuoli (NA), Italy</aff>
      <aff id="af0015"><label>b</label>Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda UniversitÃ  di Napoli, Napoli, Italy</aff>
      <aff id="af0020"><label>c</label>Fondazione Don Gnocchi, Italy</aff>
      <aff id="af0025"><label>d</label>Dipartimento di Neuroscienze e Scienze riproduttive ed odontostomatologiche, UniversitÃ  di Napoli âFederico IIâ, Napoli, Italy</aff>
      <aff id="af0030"><label>e</label>Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium</aff>
      <aff id="af0035"><label>f</label>Department of Neurology, Ghent University Hospital, Ghent, Belgium</aff>
      <aff id="af0040"><label>g</label>Biochimie et gÃ©nÃ©tique molÃ©culaire, Centre hospitalier Cochin, Paris, France</aff>
      <aff id="af0045"><label>h</label>Dipartimento di Neuroscienze, UniversitÃ  di Messina, Messina, Italy</aff>
      <aff id="af0050"><label>i</label>Dipartimento di Neuroscienze, UniversitÃ  di Padova, Padova, Italy</aff>
      <aff id="af0055"><label>j</label>Centre de RÃ©fÃ©rence Maladies Neuromusculaires â SLA, HÃ´pital Archet 1, CHU de Nice, Nice, France</aff>
      <aff id="af0060"><label>k</label>Dipartimento di Medicina Sperimentale, Seconda UniversitÃ  di Napoli, Napoli, Italy</aff>
      <author-notes>
        <corresp id="co0010"><label>*</label>Corresponding author. Laboratorio di genetica medica, Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda UniversitÃ  degli Studi di Napoli, via Luigi De Crecchio 7Â -80138 Napoli, Italy. Tel.: +39 0815665704; fax: +39 0815665704. <email>vinnigro@gmail.com</email><email>vincenzo.nigro@unina2.it</email></corresp>
        <fn id="fn0010">
          <label>1</label>
          <p>These authors contributed equally to the manuscript.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <volume>25</volume>
      <issue>7</issue>
      <fpage>533</fpage>
      <lpage>541</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>2</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2015 The Authors</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <abstract abstract-type="author-highlights">
        <title>Highlights</title>
        <p>
          <list list-type="simple">
            <list-item id="u0010">
              <label>â¢</label>
              <p>We have carried out the largest screening of the ANO5 gene.</p>
            </list-item>
            <list-item id="u0015">
              <label>â¢</label>
              <p>We identified 33 patients (4%) with pathogenic changes in both alleles and 23 heterozygotes (3%).</p>
            </list-item>
            <list-item id="u0020">
              <label>â¢</label>
              <p>The identification of a <italic>ANO5</italic> carrier is not to be considered an uncommon finding.</p>
            </list-item>
            <list-item id="u0025">
              <label>â¢</label>
              <p>The anoctaminopathies have an extremely high genetic and phenotypic heterogeneity.</p>
            </list-item>
            <list-item id="u0030">
              <label>â¢</label>
              <p>NGS-based strategies are perfect to dissect the clinical variability in NMDs.</p>
            </list-item>
          </list>
        </p>
      </abstract>
      <abstract>
        <p>We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4%) patients carrying putative pathogenic changes in both alleles and 23 <italic>ANO5</italic> heterozygotes (3%). The phenotypic spectrum is broader than expected, from hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the <italic>ANO5</italic> gene. The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents a straightforward approach to overcome the difficulties of clinical heterogeneity of <italic>ANO5</italic> patients, and to test, at the same time, many other genes involved in neuromuscular disorders.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Next generation sequencing</kwd>
        <kwd>Muscular dystrophy</kwd>
        <kwd>LGMD2L</kwd>
        <kwd>Anoctamin</kwd>
        <kwd>NGS screening</kwd>
        <kwd>Targeted resequencing</kwd>
        <kwd>Limb girdle muscular dystrophy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0010">
      <label>1</label>
      <title>Introduction</title>
      <p>The diagnosis of autosomal recessive limb-girdle muscular dystrophies (LGMDs) is complex for the presence of a number of different conditions with similar clinical presentation <xref rid="bib0010" ref-type="bibr">[1]</xref>. The genetic studies have demonstrated the involvement of at least 23 different genes for the LGMD2 forms <xref rid="bib0015" ref-type="bibr">[2]</xref> and others that are involved in metabolic, congenital or other myopathies that can also present with a clinical LGMD-like phenotype <xref rid="bib0020" ref-type="bibr">[3]</xref>. For the correct diagnosis of specific forms four elements may be of pivotal importance: 1) the clinical picture; 2) the muscle biopsy; 3) the imaging; 4) the DNA results, with the last approach that is changed dramatically in the course of the present study. We have studied one of the most interesting forms of LGMD that is caused by recessive mutations in a gene coding for a calcium-activated chloride channel, known as anoctamin 5 (<italic>ANO5</italic>) <xref rid="bib0025" ref-type="bibr">[4]</xref>. The <italic>ANO5</italic> gene at 11p14.3 spans 90,192âbp and contains 22 exons, the coding sequence is 2.7âkb for 913 amino acids. This form, according to the order of mapping, has been defined as LGMD2L. Genetic studies in some countries have shown that LGMD2L may be a very common form of LGMD <xref rid="bib0030" ref-type="bibr">[5]</xref>. In place of the proximal limb-girdle presentation, some patients show Miyoshi-like muscular dystrophy type 3 (MMD3) <xref rid="bib0035" ref-type="bibr">[6]</xref>. Dominant variations in the same gene have been associated to gnathodiaphyseal dysplasia (GDD) <xref rid="bib0040" ref-type="bibr">[7]</xref>.</p>
      <p>The LGMD2L phenotype was described for the first time in 2007 in 14 patients of French Canadian origin, showing atrophy and weakness of the quadriceps and biceps brachii muscles <xref rid="bib0045" ref-type="bibr">[8]</xref>. In 2010, <italic>ANO5</italic> was identified as the causative gene <xref rid="bib0025" ref-type="bibr">[4]</xref>. More recently, it has been indicated as the third most common form of LGMD in the North of Europe and the c.191dupA mutation has been shown to be the most prevalent because of a founder effect <xref rid="bib0030 bib0050" ref-type="bibr">[5,9]</xref>.</p>
      <p>Distinctive features of LGMD2L versus other LGMD forms are: 1) the sex imbalance, with females that are less frequently or severely affected than males <xref rid="bib0055" ref-type="bibr">[10]</xref>; 2) asymmetry of muscle involvement that is rare among the LGMD and frequent in FSH <xref rid="bib0025" ref-type="bibr">[4]</xref>; 3) the pain following exercise that is typical of metabolic or inflammatory conditions <xref rid="bib0060" ref-type="bibr">[11]</xref>.</p>
      <p>All the previous studies have evidenced the extreme heterogeneity of the observed phenotypes, comprising the asymmetric atrophy and weakness affecting primarily the quadriceps, hamstrings and biceps, an adulthood onset and a slow progression <xref rid="bib0025 bib0030 bib0055 bib0065 bib0070" ref-type="bibr">[4,5,10,12,13]</xref>. The weakness of both distal and proximal lower limbs, exercise intolerance, a so called âpseudometabolicâ phenotype and also amyloid deposits in the muscles <xref rid="bib0060 bib0075" ref-type="bibr">[11,14]</xref> are all features present in patients affected by anoctaminopathy or dysferlinopathy <xref rid="bib0080" ref-type="bibr">[15]</xref>.</p>
      <p>In this paper, we describe the results of a genetic screening in a subset of patients with a broad clinical phenotype of LGMD or generic myopathy. In total, we have fully sequenced the <italic>ANO5</italic> gene in 786 patients using Sanger and/or Next Generation Sequencing (NGS): in this cohort, we have found 33 cases belonging to 28 families. Our data confirm the genetic heterogeneity of the <italic>ANO5</italic> gene and highlight the weak genotypeâphenotype correlation.</p>
    </sec>
    <sec sec-type="methods" id="s0015">
      <label>2</label>
      <title>Methods</title>
      <sec id="s0020">
        <label>2.1</label>
        <title>Sample collection</title>
        <p>From a large collection of families with a clinical diagnosis of LGMD or with molecularly uncharacterized myopathy, we recruited 786 patients. In particular, 712/786 (90.6%) patients were from Italian families. Additional patients (nâ=â74) were from Belgium (39), France (8), Finland (4), Brazil (3), Turkey (3), Romania (3), Morocco (3), Germany (2), Russia (2), Greece (1), Israel (1), Uganda (1), Spain (1), Libya (1), Cyprus (1) and The Netherlands (1),</p>
        <p>In all the cases, genomic DNA has been tested and, when available, a further analysis on mRNA from blood or from muscle has been performed.</p>
      </sec>
      <sec id="s0025">
        <label>2.2</label>
        <title>Clinical and diagnostic criteria</title>
        <p>Based on literature evidence, as a first step, we screened 160 patients for mutations in exon 5 and in exon 20. Because of the low mutation rate detected in these exons, we extended the analysis to all the other exons.</p>
        <p>All the patients recruited for the first step have an LGMD or an LGMD-like phenotype, including a raised serum creatine kinase (CK), progressive muscle weakness affecting primarily the shoulder girdle and pelvic muscles and a muscle biopsy with dystrophic features. All of them show an autosomal recessive inheritance or are sporadic cases. Moreover, most (about 85%) of the 160 samples analyzed by PCR and Sanger sequencing had resulted negative for mutations in <italic>DYSF</italic> and <italic>CAPN3</italic> genes.</p>
        <p>Another 626 samples were recruited for NGS, including all the <italic>ANO5</italic> exons and the 10 flanking nucleotides.</p>
        <p>The inclusion criteria for the NGS screening were less stringent. Samples of still living patients, affected by an uncharacterized muscular dystrophy (65%) or myopathy (35%), were included. These patients had a wide spectrum of clinical phenotypes, ranging from an isolated hyperCKemia to mild or severe conditions with a variable age of onset and progression. A large portion of these patients (30%) had not been screened previously and less than 20% had been analyzed for mutations in LGMD recessive genes (in particular <italic>CAPN3</italic>, <italic>DYSF</italic> or sarcoglycan genes).</p>
        <p>Moreover, DNA samples from 52 unaffected people were sequenced as a control group.</p>
        <p>Written informed consent for DNA analysis was obtained from all the recruited patients or their caregivers when primary diagnostic procedures were performed, with explicit consent for future use for research purposes, according to the Declaration of Helsinki. Approval for the study was obtained by the Seconda UniversitÃ  di Napoli Ethics Committee.</p>
      </sec>
      <sec id="s0030">
        <label>2.3</label>
        <title>Molecular analysis</title>
        <p>Genomic DNA was extracted from peripheral blood by phenol/chloroform. All the <italic>ANO5</italic> exons have been amplified by PCR using M13-tailed primers. M13 primers have been used to perform Sanger sequencing using an ABI PRISM 3130 XL automatic DNA Sequencer Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). We used a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions to extract RNA from the muscle biopsies and the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) to extract RNA from the blood.</p>
        <p>The retrotranscription reaction was performed using 2âmg of total mRNA, according to the procedure described in the SuperScript III kit (Invitrogen).</p>
        <p>We amplified the <italic>ANO5</italic> cDNA in seven overlapping fragments. <xref rid="ec0015" ref-type="supplementary-material">Supplementary TableÂ S1</xref> lists primers and PCR conditions.</p>
        <p>For NGS screening, samples were enriched using HaloPlex Target Enrichment System (Protocol version D, August 2012, Agilent Technologies, Santa Clara, CA, USA) <xref rid="bib0085" ref-type="bibr">[16]</xref>.</p>
        <p>For each of the novel mutations identified, amino acid change, presence in dbSNP v137 <xref rid="bib0090" ref-type="bibr">[17]</xref>, frequency in NHLBI Exome Variant Server (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS" id="iw0010">http://evs.gs.washington.edu/EVS</ext-link>) and 1000 genomes large scale projects (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org" id="iw0015">http://www.1000genomes.org</ext-link>) <xref rid="bib0095" ref-type="bibr">[18]</xref>, conservation and causative effects, using different prediction algorithms <xref rid="bib0100 bib0105 bib0110" ref-type="bibr">[19â21]</xref>, were evaluated.</p>
        <p>To assess intronic and exonic mutations leading to splicing defects, a free bioinformatic tool (<ext-link ext-link-type="uri" xlink:href="http://www.fruitfly.org/seq_tools/splice.html" id="iw0020">http://www.fruitfly.org/seq_tools/splice.html</ext-link>) <xref rid="bib0115" ref-type="bibr">[22]</xref> was consulted.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s0035">
      <label>3</label>
      <title>Results</title>
      <p>To study 160 patients with undiagnosed LGMD, we first sequenced the hotspot regions at exons 5 and 20 of the <italic>ANO5</italic> gene, but the screening was diagnostic in two families only (I and XVI, homozygotes for c.191dupA and c.2272 Câ&gt;âT, respectively). Ten additional patients were heterozygous for a single <italic>ANO5</italic> mutation. We next extended the analysis to all the other exons by PCR and Sanger sequencing. By this exon-by-exon scanning, we were able to detect another fourteen mutations, concluding the genetic diagnosis in other 15 patients (<xref rid="t0010" ref-type="table">TableÂ 1</xref>).</p>
      <p>To profit from the extraordinary throughput of next generation sequencing <xref rid="bib0120" ref-type="bibr">[23]</xref>, we included the <italic>ANO5</italic> gene in a large and accurate screening of genes causing neuromuscular disorders <xref rid="bib0085" ref-type="bibr">[16]</xref>. In particular, the <italic>ANO5</italic> exons and the ten flanking bases were &gt;90% covered at no less than 100Ã (<xref rid="ec0010" ref-type="supplementary-material">Supplementary Fig.âS1</xref>) after a Haloplex-based enrichment. We studied further 626 patients with broader phenotypic presentation, ranging from classic LGMD phenotype to congenital myopathies, nonspecific myopathic features or hyperCKemia. In this way, we identified other 15 <italic>ANO5</italic> patients. All the variants identified by NGS were then confirmed by the dideoxy method. Interestingly, we detected different <italic>ANO5</italic> variants in both alleles in patients XVIII and XXIV. These were classified as affected by a congenital myopathy with a hypothesized dominant transmission. However, they did not show mutations in the other genes causing congenital myopathies. Considering their specific phenotype and the unavailability of other relatives' samples to study the status and the segregation of their mutations, we were not able to correctly interpret them.</p>
      <p>We also identified 23 patients with a single mutated allele, including one (XXXVIII) with two mutations <italic>in cis</italic> on the same chromosome.</p>
      <p>To avoid the risk to miss mutations, the DNA samples from heterozygous patients were also resequenced exon-by-exon and no additional variations were detected. Array-CGH (Motorchip <xref rid="bib0125" ref-type="bibr">[24]</xref>) testing was also negative.</p>
      <p>Finally, three normal control samples also showed heterozygous variants in <italic>ANO5</italic>, including a novel missense substitution (ctrl1).</p>
      <p>By combining NGS and Sanger sequencing, we identified 33/786 individuals, from 28 different families, homozygous or compound heterozygous for mutations in the <italic>ANO5</italic> gene. Forty-three mutations were detected in 16/22 exons. Twelve of them had already been detected and described in literature; on the contrary, thirty-one had never been described previously (<xref rid="t0010" ref-type="table">TableÂ 1</xref>).</p>
      <sec id="s0040">
        <label>3.1</label>
        <title>Novel mutations</title>
        <sec id="s0045">
          <label>3.1.1</label>
          <title>Missense and nonsense mutations</title>
          <p>Twenty-four novel missense and nonsense mutations were detected. In particular, four of them (c.1207 Câ&gt;âT, c.1213 Câ&gt;âT, c.1261 Câ&gt;âT and c.1639 Câ&gt;âT) introduced a premature stop codon. All the other variants determined an amino acidic change and their clinical significance was evaluated by different bioinformatic tools.</p>
          <p>The mutations identified in homozygosity (c.161 Tâ&gt;âC in II and c.2498 Tâ&gt;âA in VII) or in compound heterozygosity (c.2489 Câ&gt;âT in XV, c.2342 in XLV and c.2411Câ&gt;âG in XLII) were all predicted to be causative by at least two out of three tools.</p>
        </sec>
        <sec id="s0050">
          <label>3.1.2</label>
          <title>Point mutations modifying a splicing site consensus</title>
          <p>Four point mutations (c.294 Gâ&gt;âA; c.649-2 Aâ&gt;âG; c.1119â+â1 Gâ&gt;âA and c.2235â+â1 Gâ&gt;âA) were expected to modify a splicing site, as suggested by bioinformatic tools. We analyzed <italic>ANO5</italic> mRNA in the leukocytes (for patient XXII) or in the muscle (V), to confirm the splicing effect. As detected on control samples, the leukocyte <italic>ANO5</italic> isoform lacks exon 4, but maintains the reading frame and determines a predicted protein 14 amino acids smaller (<xref rid="f0010" ref-type="fig">Fig.â1</xref>).</p>
          <p>In patient XXII, the mutation produces a shortened mRNA without exons 4 and 5 (<xref rid="f0015" ref-type="fig">Fig.â2A, B</xref>). The extra-skipping of exon 5 causes an in-frame deletion of 114 nucleotides encoding 38 amino acids. However, both DNA and RNA analyses did not allow us to detect a second mutation in this patient that remains formally undiagnosed.</p>
          <p>The muscular mRNA of patient V revealed the activation of a cryptic splice site 20 nucleotides upstream the natural 3â² end of exon 11 (<xref rid="f0015" ref-type="fig">Fig.â2CâD</xref>). The frame-shift results in a premature stop codon after five amino acids. For splice site mutations in patients XIX and XX, we did not study muscle mRNA, but there is little doubt about their deleterious effect.</p>
        </sec>
        <sec id="s0055">
          <label>3.1.3</label>
          <title>Small deletions and insertions</title>
          <p>We found two small deletions in the same patient (VI). In particular, in exon 6 we detected a c. 304â308 delAAAGA, causing a frame-shift with the substitution of a Lysine with a Valine 102 and a premature stop codon after a single amino acidic residue.</p>
          <p>In exon 19, we found a 3-nucleotide deletion c. 2102â2105 delATA, causing the loss of an Asparagine 701. This residue, evolutionarily conserved, is the first amino acid of the putative sixth cytoplasmatic loop and its loss is predicted to be damaging.</p>
          <p>An insertion of a single nucleotide was found in one allele of patient XLVII and it determined an immediate premature stop codon.</p>
        </sec>
      </sec>
      <sec id="s0060">
        <label>3.2</label>
        <title>Phenotypic spectrum of <italic>ANO5</italic> patients</title>
        <p>As already reported <xref rid="bib0055" ref-type="bibr">[10]</xref>, also in our cohort of patients, the number of affected males (21â=â64%) was higher than that of females (12â=â36%). The age of onset varied significantly (meanâ=â26.81; minâ=â13; maxâ=â44). Interestingly, four <italic>ANO5</italic> patients (IV,1; IV,2; X,2; XIV,2) are still asymptomatic even if they showed increased CK serum levels. The average CK values were 3200âIU/l ranging from 500âIU/l to 9800âIU/l.</p>
        <p>The clinical signs of patients with LGMD2L presentation, such as the early asymmetric quadriceps weakness, the high CK and the slow progression, and the histological features, including mild myopathic changes, were in agreement with literature data (<xref rid="t0015" ref-type="table">TableÂ 2</xref>) <xref rid="bib0070 bib0130 bib0135 bib0140" ref-type="bibr">[13,25â27]</xref>. All the patients are still ambulant, but two that occasionally use walking aids (aged 71 and 75).</p>
        <p>When assessed, cardiac and respiratory functions were normal with the exception of patient V, who showed a short PQ interval, and of patient XII, who is suffering from a restrictive respiratory insufficiency.</p>
        <p>For 15 families, a brief summary of the phenotype was added as Supplementary appendix. Patients XV, XVI and XVII have been previously characterized elsewhere <xref rid="bib0070" ref-type="bibr">[13]</xref>.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s0065">
      <label>4</label>
      <title>Discussion</title>
      <p>By combining NGS and Sanger sequencing, we have carried out the largest screening of the <italic>ANO5</italic> gene in 786 myopathic patients and 52 controls. In our cohort of patients, thirty-three are homozygous or compound heterozygous for causative mutations in <italic>ANO5</italic>. Interestingly only 18/33 are Italian (although they are 90% of the cohort), providing a further evidence of lower frequency of anoctaminopathies in this country <xref rid="bib0065" ref-type="bibr">[12]</xref> where dysferlinopathies and calpainopathies still remain the most common form of LGMD <xref rid="bib0145" ref-type="bibr">[28]</xref>. In contrast, we have evidenced a single heterozygous variant in 3% (23/786) of patients. Some of these may be non-pathological rare variants, but others, such as c.191dupA, are well-known causative mutations. When fully studied, heterozygous patients show no hidden mutation on the second allele. Is this compatible with the disease prevalence? Previous published papers have evidenced the high prevalence of anoctaminopathies in Northern Europe: in particular, a prevalence of 0.27/100,000 has been estimated in the North of England <xref rid="bib0030" ref-type="bibr">[5]</xref> and of 2/100,000 in the Finnish population <xref rid="bib0070" ref-type="bibr">[13]</xref>. However, a rarer frequency of variants has been reported elsewhere <xref rid="bib0065" ref-type="bibr">[12]</xref>.</p>
      <p>To explain 3% of heterozygotes, we propose two hypotheses:</p>
      <p>
        <list list-type="simple">
          <list-item id="o0035">
            <label>1</label>
            <p>We would find a similar number of heterozygotes in any other cohort of subjects, because the frequency of pathological alleles is at least 10-fold higher than expected (&gt;0.01 instead of 0.001). This immediately indicates that over 90% of cases with both <italic>ANO5</italic> mutations should be quite healthy, in the absence of a second unknown hit.</p>
          </list-item>
          <list-item id="o0040">
            <label>2</label>
            <p>We have found many heterozygous subjects, because they are true patients: this suggests that <italic>ANO5</italic>-myopathy could be transmitted as a dominant trait, in the presence of a second unknown hit. A point in favor of the first hypothesis is the long list of <italic>ANO5</italic> variants present in the Exome Variant Server and in dbSNP: <italic>ANO5</italic> is certainly a highly polymorphic gene. In fact, eighty variants with a frequency lower than 1.5% are listed in EVS (<xref rid="ec0020" ref-type="supplementary-material">Supplementary TableÂ S2</xref>) for a total of 959 carriers; 20 subjects (0.3%) are heterozygous for the well-known c.191 dupA and 159 (2.4%) show a putative damaging variant (total 3%). The identification of a carrier of a single mutation in <italic>ANO5</italic> gene is not to be considered an uncommon finding and it will be important to identify a second putative hit. Since deleterious copy number imbalances have been estimated in 5â10% of patients affected by neuromuscular disorders <xref rid="bib0125" ref-type="bibr">[24]</xref>, copy number variants involving noncoding regulatory regions <xref rid="bib0150 bib0155" ref-type="bibr">[29,30]</xref> could affect the <italic>ANO5</italic> expression in some tissues. Other explanations involve mutations in other genes belonging to the same pathway, the effect of modifier genes, epigenetic changes or environmental factors.</p>
          </list-item>
        </list>
      </p>
      <p>Interestingly, the phenotypeâgenotype analysis shows the absence of a correlation. All the asymptomatic patients have increased creatine kinase levels, supporting the hypothesis of the variable expressivity of <italic>ANO5</italic> myopathy. In our cases, the expressivity seems to be independent of causative mutations and also unrelated to sex and age. In particular, the lack of a clear genotypeâphenotype correlation is evident either comparing different families or even focusing on different patients within the same family (for example, the patient X,2, still asymptomatic, has a younger brother presenting with cramps and myalgia). The interfamilial variability could reflect a specific genetic background and the putative presence of a second hit, as postulated. On the contrary, the intra-familial heterogeneity could be due to different external factors, including lifestyle, sport activity and diet, which should be further investigated.</p>
      <p>The anoctaminopathies are also characterized by an extremely high genetic heterogeneity <xref rid="bib0055 bib0130" ref-type="bibr">[10,25]</xref>. Interestingly, among our patients with a complete molecular diagnosis of anoctaminopathy, c.191dupA and c.2272Câ&gt;âT, the most common variation described so far, represent less than 30% of identified mutations and they both account for only 20% of those detected in the Italian patients. On the contrary, we have identified 31 novel variants, confirming the genetic heterogeneity of <italic>ANO5</italic> and demonstrating that the simple screening of one or two recurrent mutations cannot be considered effective in Southern European populations (<xref rid="f0020" ref-type="fig">Fig.â3</xref>).</p>
      <p>Considering the power of next generation sequencing <xref rid="bib0120" ref-type="bibr">[23]</xref> and the clinical and genetic variability of muscular dystrophies, diagnostic approaches based on NGS are becoming increasingly frequent <xref rid="bib0160" ref-type="bibr">[31]</xref>. However, for clinical and diagnostic aims, a targeted resequencing of genes already known to be linked to the specific pathological condition is advisable <xref rid="bib0165" ref-type="bibr">[32]</xref> and <italic>ANO5</italic> has to be included. Our data also demonstrate the utility of this approach, highlighting, however, how important the correct interpretation of the data generated by these approaches could be. Moreover, these NGS-based strategies are perfect to dissect the clinical variability <xref rid="bib0170" ref-type="bibr">[33]</xref>, meeting, in this way, with the next challenges of research.</p>
      <p>In conclusion, we suggest that the terms âanoctaminopathyâ or â<italic>ANO5</italic> myopathyâ better define a heterogeneous disease caused by mutations in the <italic>ANO5</italic> gene, irrespective of the first proximal (LGMD2L), distal symptoms (Miyoshi myopathy) or characterized by other myopathic features.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0010">
        <label>1</label>
        <element-citation publication-type="journal" id="sr0010">
          <person-group person-group-type="author">
            <name>
              <surname>Eymard</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic strategy for limb-girdle muscular dystrophies</article-title>
          <source>Rev Neurol (Paris)</source>
          <volume>168</volume>
          <year>2012</year>
          <fpage>919</fpage>
          <lpage>926</lpage>
          <pub-id pub-id-type="pmid">22677325</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>2</label>
        <element-citation publication-type="journal" id="sr0015">
          <person-group person-group-type="author">
            <name>
              <surname>Nigro</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Savarese</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Genetic basis of limb-girdle muscular dystrophies: the 2014 update</article-title>
          <source>Acta Myol</source>
          <volume>33</volume>
          <year>2014</year>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">24843229</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>3</label>
        <element-citation publication-type="journal" id="sr0020">
          <person-group person-group-type="author">
            <name>
              <surname>Mercuri</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Muntoni</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Muscular dystrophies</article-title>
          <source>Lancet</source>
          <volume>381</volume>
          <year>2013</year>
          <fpage>845</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="pmid">23465426</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>4</label>
        <element-citation publication-type="journal" id="sr0025">
          <person-group person-group-type="author">
            <name>
              <surname>Bolduc</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Marlow</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Boycott</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies</article-title>
          <source>Am J Hum Genet</source>
          <volume>86</volume>
          <year>2010</year>
          <fpage>213</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="pmid">20096397</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>5</label>
        <element-citation publication-type="journal" id="sr0030">
          <person-group person-group-type="author">
            <name>
              <surname>Hicks</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sarkozy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Muelas</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy</article-title>
          <source>Brain</source>
          <volume>134</volume>
          <year>2011</year>
          <fpage>171</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="pmid">21186264</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>6</label>
        <element-citation publication-type="journal" id="sr0035">
          <person-group person-group-type="author">
            <name>
              <surname>Mahjneh</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Jaiswal</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lamminen</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A new distal myopathy with mutation in anoctamin 5</article-title>
          <source>Neuromuscul Disord</source>
          <volume>20</volume>
          <year>2010</year>
          <fpage>791</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="pmid">20692837</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>7</label>
        <element-citation publication-type="journal" id="sr0040">
          <person-group person-group-type="author">
            <name>
              <surname>Tsutsumi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kamata</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Vokes</surname>
              <given-names>T.J.</given-names>
            </name>
          </person-group>
          <article-title>The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD)</article-title>
          <source>Am J Hum Genet</source>
          <volume>74</volume>
          <year>2004</year>
          <fpage>1255</fpage>
          <lpage>1261</lpage>
          <pub-id pub-id-type="pmid">15124103</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0045">
        <label>8</label>
        <element-citation publication-type="journal" id="sr0045">
          <person-group person-group-type="author">
            <name>
              <surname>Jarry</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rioux</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Bolduc</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12</article-title>
          <source>Brain</source>
          <volume>130</volume>
          <year>2007</year>
          <fpage>368</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">17008331</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0050">
        <label>9</label>
        <element-citation publication-type="journal" id="sr0050">
          <person-group person-group-type="author">
            <name>
              <surname>Witting</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Duno</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Petri</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression</article-title>
          <source>J Neurol</source>
          <volume>260</volume>
          <year>2013</year>
          <fpage>2084</fpage>
          <lpage>2093</lpage>
          <pub-id pub-id-type="pmid">23670307</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0055">
        <label>10</label>
        <element-citation publication-type="journal" id="sr0055">
          <person-group person-group-type="author">
            <name>
              <surname>Sarkozy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hicks</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation</article-title>
          <source>Hum Mutat</source>
          <volume>34</volume>
          <year>2013</year>
          <fpage>1111</fpage>
          <lpage>1118</lpage>
          <pub-id pub-id-type="pmid">23606453</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0060">
        <label>11</label>
        <element-citation publication-type="journal" id="sr0060">
          <person-group person-group-type="author">
            <name>
              <surname>Milone</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Liewluck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Winder</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Pianosi</surname>
              <given-names>P.T.</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis and exercise intolerance in ANO5 muscular dystrophy</article-title>
          <source>Neuromuscul Disord</source>
          <volume>22</volume>
          <year>2011</year>
          <fpage>13</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">21820307</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0065">
        <label>12</label>
        <element-citation publication-type="journal" id="sr0065">
          <person-group person-group-type="author">
            <name>
              <surname>Magri</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bo</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>D'Angelo</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Frequency and characterisation of anoctamin 5 mutations in a cohort of Italian limb-girdle muscular dystrophy patients</article-title>
          <source>Neuromuscul Disord</source>
          <volume>22</volume>
          <year>2012</year>
          <fpage>934</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">22742934</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0070">
        <label>13</label>
        <element-citation publication-type="journal" id="sr0070">
          <person-group person-group-type="author">
            <name>
              <surname>Penttila</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Palmio</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Suominen</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5</article-title>
          <source>Neurology</source>
          <volume>78</volume>
          <year>2012</year>
          <fpage>897</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="pmid">22402862</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0075">
        <label>14</label>
        <element-citation publication-type="journal" id="sr0075">
          <person-group person-group-type="author">
            <name>
              <surname>Liewluck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Winder</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Dimberg</surname>
              <given-names>E.L.</given-names>
            </name>
          </person-group>
          <article-title>ANO5-muscular dystrophy: clinical, pathological and molecular findings</article-title>
          <source>Eur J Neurol</source>
          <volume>20</volume>
          <year>2013</year>
          <fpage>1383</fpage>
          <lpage>1389</lpage>
          <pub-id pub-id-type="pmid">23663589</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0080">
        <label>15</label>
        <element-citation publication-type="journal" id="sr0080">
          <person-group person-group-type="author">
            <name>
              <surname>Cacciottolo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Numitone</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Aurino</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations</article-title>
          <source>Eur J Hum Genet</source>
          <volume>19</volume>
          <year>2011</year>
          <fpage>974</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="pmid">21522182</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0085">
        <label>16</label>
        <element-citation publication-type="journal" id="sr0085">
          <person-group person-group-type="author">
            <name>
              <surname>Savarese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Di Fruscio</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mutarelli</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples</article-title>
          <source>Acta Neuropathol Commun</source>
          <volume>2</volume>
          <year>2014</year>
          <fpage>100</fpage>
          <pub-id pub-id-type="pmid">25214167</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0090">
        <label>17</label>
        <element-citation publication-type="journal" id="sr0090">
          <person-group person-group-type="author">
            <name>
              <surname>Sherry</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Kholodov</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>dbSNP: the NCBI database of genetic variation</article-title>
          <source>Nucleic Acids Res</source>
          <volume>29</volume>
          <year>2001</year>
          <fpage>308</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">11125122</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0095">
        <label>18</label>
        <element-citation publication-type="journal" id="sr0095">
          <person-group person-group-type="author">
            <name>
              <surname>Abecasis</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Altshuler</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Auton</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A map of human genome variation from population-scale sequencing</article-title>
          <source>Nature</source>
          <volume>467</volume>
          <year>2010</year>
          <fpage>1061</fpage>
          <lpage>1073</lpage>
          <pub-id pub-id-type="pmid">20981092</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0100">
        <label>19</label>
        <element-citation publication-type="journal" id="sr0100">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Henikoff</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>P.C.</given-names>
            </name>
          </person-group>
          <article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>
          <source>Nat Protoc</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>1073</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="pmid">19561590</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0105">
        <label>20</label>
        <element-citation publication-type="journal" id="sr0105">
          <person-group person-group-type="author">
            <name>
              <surname>Adzhubei</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Sunyaev</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Predicting functional effect of human missense mutations using PolyPhen-2</article-title>
          <source>Curr Protoc Hum Genet</source>
          <year>2013</year>
          <comment>Chapter 7:Unit7 20</comment>
        </element-citation>
      </ref>
      <ref id="bib0110">
        <label>21</label>
        <element-citation publication-type="journal" id="sr0110">
          <person-group person-group-type="author">
            <name>
              <surname>Schwarz</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Rodelsperger</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Schuelke</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Seelow</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>MutationTaster evaluates disease-causing potential of sequence alterations</article-title>
          <source>Nat Methods</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>575</fpage>
          <lpage>576</lpage>
          <pub-id pub-id-type="pmid">20676075</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0115">
        <label>22</label>
        <element-citation publication-type="journal" id="sr0115">
          <person-group person-group-type="author">
            <name>
              <surname>Reese</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Eeckman</surname>
              <given-names>F.H.</given-names>
            </name>
            <name>
              <surname>Kulp</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Haussler</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Improved splice site detection in Genie</article-title>
          <source>J Comput Biol</source>
          <volume>4</volume>
          <year>1997</year>
          <fpage>311</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="pmid">9278062</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0120">
        <label>23</label>
        <element-citation publication-type="journal" id="sr0120">
          <person-group person-group-type="author">
            <name>
              <surname>Desai</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Jere</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Next-generation sequencing: ready for the clinics?</article-title>
          <source>Clin Genet</source>
          <volume>81</volume>
          <year>2012</year>
          <fpage>503</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">22375550</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0125">
        <label>24</label>
        <element-citation publication-type="journal" id="sr0125">
          <person-group person-group-type="author">
            <name>
              <surname>Piluso</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Dionisi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Del Vecchio Blanco</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disorders</article-title>
          <source>Clin Chem</source>
          <volume>57</volume>
          <year>2011</year>
          <fpage>1584</fpage>
          <lpage>1596</lpage>
          <pub-id pub-id-type="pmid">21896784</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0130">
        <label>25</label>
        <element-citation publication-type="book" id="sr0130">
          <person-group person-group-type="author">
            <name>
              <surname>Penttila</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Palmio</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Udd</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <chapter-title>ANO5-Related Muscle Diseases</chapter-title>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="bib0135">
        <label>26</label>
        <element-citation publication-type="journal" id="sr0135">
          <person-group person-group-type="author">
            <name>
              <surname>Schessl</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kress</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schoser</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy</article-title>
          <source>Muscle Nerve</source>
          <volume>45</volume>
          <year>2012</year>
          <fpage>740</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">22499103</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0140">
        <label>27</label>
        <element-citation publication-type="journal" id="sr0140">
          <person-group person-group-type="author">
            <name>
              <surname>Sarkozy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Deschauer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Carlier</surname>
              <given-names>R.Y.</given-names>
            </name>
          </person-group>
          <article-title>Muscle MRI findings in limb girdle muscular dystrophy type 2L</article-title>
          <source>Neuromuscul Disord</source>
          <volume>22</volume>
          <issue>Suppl. 2</issue>
          <year>2012</year>
          <fpage>S122</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">22980763</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0145">
        <label>28</label>
        <element-citation publication-type="journal" id="sr0145">
          <person-group person-group-type="author">
            <name>
              <surname>Fanin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nascimbeni</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Aurino</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes</article-title>
          <source>Neurology</source>
          <volume>72</volume>
          <year>2009</year>
          <fpage>1432</fpage>
          <lpage>1435</lpage>
          <pub-id pub-id-type="pmid">19380703</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0150">
        <label>29</label>
        <element-citation publication-type="journal" id="sr0150">
          <person-group person-group-type="author">
            <name>
              <surname>Savarese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Piluso</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Orteschi</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Enhancer chip: detecting human copy number variations in regulatory elements</article-title>
          <source>PLoS ONE</source>
          <volume>7</volume>
          <year>2012</year>
          <fpage>e52264</fpage>
          <pub-id pub-id-type="pmid">23284961</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0155">
        <label>30</label>
        <element-citation publication-type="journal" id="sr0155">
          <person-group person-group-type="author">
            <name>
              <surname>Spielmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Klopocki</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>CNVs of noncoding cis-regulatory elements in human disease</article-title>
          <source>Curr Opin Genet Dev</source>
          <volume>23</volume>
          <year>2013</year>
          <fpage>249</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="pmid">23601627</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0160">
        <label>31</label>
        <element-citation publication-type="journal" id="sr0160">
          <person-group person-group-type="author">
            <name>
              <surname>Vasli</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Laporte</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders</article-title>
          <source>Acta Neuropathol</source>
          <volume>125</volume>
          <year>2013</year>
          <fpage>173</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">23224362</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0165">
        <label>32</label>
        <element-citation publication-type="journal" id="sr0165">
          <person-group person-group-type="author">
            <name>
              <surname>Rehm</surname>
              <given-names>H.L.</given-names>
            </name>
          </person-group>
          <article-title>Disease-targeted sequencing: a cornerstone in the clinic</article-title>
          <source>Nat Rev Genet</source>
          <volume>14</volume>
          <year>2013</year>
          <fpage>295</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">23478348</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0170">
        <label>33</label>
        <element-citation publication-type="journal" id="sr0170">
          <person-group person-group-type="author">
            <name>
              <surname>Nigro</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Piluso</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Next generation sequencing (NGS) strategies for the genetic testing of myopathies</article-title>
          <source>Acta Myol</source>
          <volume>31</volume>
          <year>2012</year>
          <fpage>196</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">23620651</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="s9015" sec-type="supplementary-material">
      <label>Appendix</label>
      <title>Supplementary material</title>
      <p>The following is the supplementary data to this article:<supplementary-material content-type="local-data" id="ec0010"><caption><title>FigÂ S1</title><p>Supplementary Figure 1 shows the average sequencing coverage of ANO5 gene.</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material></p>
      <p>
        <supplementary-material content-type="local-data" id="ec0015">
          <caption>
            <title>TableÂ S1</title>
            <p>Supplementary Tables e1 contains the list of PCR and RT-PCR primers.</p>
          </caption>
          <media xlink:href="mmc2.xls"/>
        </supplementary-material>
      </p>
      <p>
        <supplementary-material content-type="local-data" id="ec0020">
          <caption>
            <title>TableÂ S2</title>
            <p>Supplementary Table e2 enumerates all the rare ANO5 variants of unknown significance.</p>
          </caption>
          <media xlink:href="mmc3.xls"/>
        </supplementary-material>
      </p>
      <p>
        <supplementary-material content-type="local-data" id="ec9025">
          <caption>
            <title>AppendixÂ S1</title>
            <p>Supplementary text describes the clinical features of ANO5 patients</p>
          </caption>
          <media xlink:href="mmc4.docx"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ac0010">
      <title>Acknowledgments</title>
      <p>We thank all the patients and their families for their contribution to this work. We acknowledge Claudio Bruno, Filippo Maria Santorelli, Chiara Fiorillo, Giacomo Pietro Comi, Francesca Magri, Maurizio Moggio and the Italian Networks for LGMD and CM. We acknowledge Anna Cuomo and Rosalba Erpice for Sanger sequencing and Jonathan Cole for manuscript proofreading. We also thank the TIGEM Bioinformatics Core for support in data analysis.</p>
    </ack>
    <fn-group>
      <fn id="s0070" fn-type="supplementary-material">
        <p>Supplementary data to this article can be found online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.nmd.2015.03.011" id="iw0025">doi:10.1016/j.nmd.2015.03.011</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="f0010">
      <label>Fig.Â 1</label>
      <caption>
        <p>Alternative splicing of exon 4. <italic>ANO5</italic> mRNA in muscle shows the full-length isoform containing the exon 4 (A). Blood isoform is differentially spliced, the exon 4 is removed and the exon 3 is directly joined with the exon 5 (B).</p>
      </caption>
      <graphic xlink:href="nmd3024-fig-0001"/>
    </fig>
    <fig id="f0015">
      <label>Fig.Â 2</label>
      <caption>
        <p>Intronic mutations affecting the splicing in patients XIX and V. In patient XIX, the Gâ&gt;âA mutation in the last exonic nucleotide (A) causes the loss of the canonical splicing site (B). In blood cDNA, the sequence shows the normal splicing, which connects exon 3 and exon 5, and the abnormal splicing with the complete loss of exon 4. In patient V, the Gâ&gt;âA mutation in the first intronic nucleotide (C) causes the activation of a cryptic splicing site twenty nucleotides upstream (D), as evidenced on muscular cDNA. The loss of the last twenty nucleotides of exon 11 produces a frame-shift and a premature stop codon five amino acids later.</p>
      </caption>
      <graphic xlink:href="nmd3024-fig-0002"/>
    </fig>
    <fig id="f0020">
      <label>Fig.Â 3</label>
      <caption>
        <p>Locations of <italic>ANO5</italic> mutations. Black label: previously reported recessive mutations. Red label: novel mutations reported in this study. Splice mutations for which their effect on the mRNA has not been verified have been omitted.</p>
      </caption>
      <graphic xlink:href="nmd3024-fig-0003"/>
    </fig>
    <table-wrap id="t0010" position="float">
      <label>TableÂ 1</label>
      <caption>
        <p>List of patients and controls with ANO5 variants.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Sample ID</th>
            <th align="left">Status</th>
            <th align="left">Mutations</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">I,1<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">I,2<sup>f</sup></td>
            <td align="left">hom</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">II<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">
              <bold>c.161Tâ&gt;âC (exon 4) p.Phe54Ser</bold>
            </td>
          </tr>
          <tr>
            <td align="left">III<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">c.172Câ&gt;âT (exon 4) p.Arg58Trp<sup>31</sup></td>
          </tr>
          <tr>
            <td align="left">IV,1<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.1733Tâ&gt;âC (exon 16) p.Phe578Ser<sup>8</sup>â+âc.2272Câ&gt;âT (exon 20) p.Arg758Cys<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">IV,2<sup>f</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.1733Tâ&gt;âC (exon 16) p.Phe578Ser<sup>8</sup>â+âc.2272Câ&gt;âT (exon 20) p.Arg758Cys<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">V<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left"><bold>c.1119</bold>â<bold>+</bold>â<bold>1 G</bold>â<bold>&gt;</bold>â<bold>A (exon 11) p.Ser367IlefsX5</bold>â+âc.2272Câ&gt;âT (exon 20) p.Arg758Cys<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">VI<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left"><bold>c.304â308 delAAAGA (exon 6) p.Lys102ValfsX1</bold>â<bold>+</bold>â<bold>c.2102â2105 delATA (exon 19) p.ÎAsn701</bold></td>
          </tr>
          <tr>
            <td align="left">VII<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">
              <bold>c.2498Tâ&gt;âA (exon 21) p. Met833Lys</bold>
            </td>
          </tr>
          <tr>
            <td align="left">VIII<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">
              <bold>c.1639Câ&gt;âT (exon 16) p.Arg547X</bold>
            </td>
          </tr>
          <tr>
            <td align="left">IX,1<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.1733Tâ&gt;âC (exon 16) p. Phe578Ser<sup>8</sup></td>
          </tr>
          <tr>
            <td align="left">IX,2<sup>f</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.1733Tâ&gt;âC (exon 16) p. Phe578Ser<sup>8</sup></td>
          </tr>
          <tr>
            <td align="left">X,1<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.2516Tâ&gt;âG (exon 21) p.Met839Arg<sup>16</sup></td>
          </tr>
          <tr>
            <td align="left">X,2<sup>f</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.2516Tâ&gt;âG (exon 21) p.Met839Arg<sup>16</sup></td>
          </tr>
          <tr>
            <td align="left">XI<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+â<bold>c.1261Câ&gt;âT (exon 13) p.Gln421X</bold></td>
          </tr>
          <tr>
            <td align="left">XII<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left">c.692Gâ&gt;âT (exon 8) p.Gly231Val<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XIII<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XIV,1<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left">c.1627dupA (exon 15) p.Met543Asn fsX10<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XIV,2<sup>f</sup></td>
            <td align="left">hom</td>
            <td align="left">c.1627dupA (exon 15) p.Met543Asn fsX10<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XV<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+â<bold>c.2489Câ&gt;âT (exon 21) p.Ala830Val</bold></td>
          </tr>
          <tr>
            <td align="left">XVI<sup>s</sup></td>
            <td align="left">hom</td>
            <td align="left">c.2272Câ&gt;âT (exon 20) p.Arg758Cys<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XVII<sup>s</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.1520 delT (exon 15) p.Phe507SerfsX6<sup>17</sup>â+âc.1898-4Aâ&gt;âG (exon 18) spl.?<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XVIII<sup>ngs</sup></td>
            <td align="left">het/c.het</td>
            <td align="left"><bold>c.616Aâ&gt;âG (exon 7) p.Thr206Ala</bold>â<bold>+</bold>â<bold>c.1211Gâ&gt;âT (exon 13) p.Arg404Leu</bold></td>
          </tr>
          <tr>
            <td align="left">XIX<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left"><bold>c.2235</bold>â<bold>+</bold>â<bold>1Gâ&gt;âA (exon19) spl.?</bold></td>
          </tr>
          <tr>
            <td align="left">XX<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left">
              <bold>c.649-2Aâ&gt;âG (exon8) spl.?</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXI<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+â<bold>c.1213Câ&gt;âT (exon 13) p.Gln405X</bold></td>
          </tr>
          <tr>
            <td align="left">XXII<sup>s</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.294Gâ&gt;âA(exon 5) p.Ala98Ala spl.?</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXIII<sup>s</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.1640Gâ&gt;âA (exon 16) p.Arg547Gln</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXIV<sup>ngs</sup></td>
            <td align="left">het/c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XXV<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.2698Aâ&gt;âC (exon 22) p.Met900Leu</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXVI<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.279Câ&gt;âG (exon 5) p.Asp93Glu</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXVII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left"><bold>c.797 C</bold>â<bold>&gt;</bold>â<bold>T (exon 9) p.Pro266Leu</bold></td>
          </tr>
          <tr>
            <td align="left">XXVIII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.428Aâ&gt;âG (exon 7) p.Tyr143Cys</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXIX<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.777Gâ&gt;âT (exon 9) p.Lys259Asn</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXX<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2141Câ&gt;âG (exon 19) p.Thr714Ser<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XXXI<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.294Gâ&gt;âA(exon 5) p.Ala98Ala spl.?</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXXII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2141Câ&gt;âG (exon 19) p.Thr714Ser<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XXXIII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.604Gâ&gt;âA (exon 7) p.Glu202Lys</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXXIV<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.800Câ&gt;âG (exon 9) p.Thr267Ser</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXXV<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.692Gâ&gt;âT (exon 8) p.Gly231Val<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XXXVI<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.155Aâ&gt;âG (exon4) p.Asn52Ser<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XXXVII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.1664Gâ&gt;âT (exon 16) p.Ser555Ile</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XXXVIII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left"><bold>c.259Gâ&gt;âA p.Val87Ile (exon 5)</bold>â+âc.692Gâ&gt;âT (exon 8) p.Gly231Val<sup>6</sup> [in cis]</td>
          </tr>
          <tr>
            <td align="left">XXXIX<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XL<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XLI<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.794Aâ&gt;âG (exon9) p.Asn265Ser</bold>
            </td>
          </tr>
          <tr>
            <td align="left">XLII<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left"><bold>c.1207Câ&gt;âT (exon 13) p.Gln403X</bold>â<bold>+</bold>â<bold>c.2411Câ&gt;âG (exon 20) p.Cys804Ser</bold></td>
          </tr>
          <tr>
            <td align="left">XLIII<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup>â+âc.1520 delT (exon 15) p.Phe507SerfsX6<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">XLIV<sup>ngs</sup></td>
            <td align="left">hom</td>
            <td align="left">c.191 dupA (exon 5) p.Asn64LysfsX15<sup>6</sup></td>
          </tr>
          <tr>
            <td align="left">XLV<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left">c.692Gâ&gt;âT (exon 8) p.Gly231Val<sup>6</sup>â+â<bold>c.2342Tâ&gt;âC (exon 20) p.Leu781Pro</bold></td>
          </tr>
          <tr>
            <td align="left">XLVI<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left"><bold>c.1213Câ&gt;âT (exon 13) p.Gln405X</bold>â+âc.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XLVII<sup>ngs</sup></td>
            <td align="left">c.het</td>
            <td align="left"><bold>c.729_730insT (exon 8) p.Asn244X</bold>â+âc.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XLVIII<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.155Aâ&gt;âG (exon4) p.Asn52Ser<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">XLIX<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.1516Aâ&gt;âG (exon15) p.Ser506Gly</bold>
            </td>
          </tr>
          <tr>
            <td align="left">L<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2141Câ&gt;âG (exon 19) p.Thr714Ser<sup>17</sup></td>
          </tr>
          <tr>
            <td align="left">LI<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2516Tâ&gt;âG (exon 21) p.Met839Arg<sup>16</sup></td>
          </tr>
          <tr>
            <td align="left">ctrl1<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">
              <bold>c.1854Gâ&gt;âC (exon 17) p.Met618Ile</bold>
            </td>
          </tr>
          <tr>
            <td align="left">ctrl2<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
          <tr>
            <td align="left">ctrl3<sup>ngs</sup></td>
            <td align="left">het</td>
            <td align="left">c.2387Câ&gt;âT (exon20) p.Ser796Leu<sup>32</sup></td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>sâ=âSanger sequencing; fâ=âfamilial; ngsâ=âNGS analysis; homâ=âhomozygous; hetâ=âheterozygous; c.hetâ=âcompound heterozygous.</p>
          <p>Novel mutations are in bold.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t0015" position="float">
      <label>TableÂ 2</label>
      <caption>
        <p>Clinical features.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Patient ID</th>
            <th align="left">Sex</th>
            <th align="left">Current age</th>
            <th align="left">Age of onset</th>
            <th align="left">CK, IU/l, range</th>
            <th align="left">ECG and ultrasound</th>
            <th align="left">Spirometry</th>
            <th align="left">Clinical phenotype</th>
            <th align="left">Biopsy</th>
            <th align="left">Loss of walking</th>
            <th align="left">Genotype</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">I,1</td>
            <td align="left">M</td>
            <td align="left">63</td>
            <td align="left">37</td>
            <td align="left">2800â9800</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia, lower quadriceps pain and later mild weakness</td>
            <td align="left">Muscular dystrophy with regenerating and necrotic fibers, variation in fibers size (small and hypertrophic)</td>
            <td align="left">No</td>
            <td rowspan="2" align="left">c.191 dupA; p.Asn64LysfsX15â+âc.191 dupA; p.Asn64LysfsX15</td>
          </tr>
          <tr>
            <td align="left">I,2</td>
            <td align="left">F</td>
            <td align="left">35</td>
            <td align="left">32</td>
            <td align="left">2000â3000</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Hyper-CK-emia, followed by lower quadriceps pain doing stairs</td>
            <td align="left">NA</td>
            <td align="left">No</td>
          </tr>
          <tr>
            <td align="left">II</td>
            <td align="left">M</td>
            <td align="left">51</td>
            <td align="left">36</td>
            <td align="left">3000â7000</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Weakness of ankle plantar flexors, hamstrings and quadriceps, hypotrophy</td>
            <td align="left">Mild dystrophic changes</td>
            <td align="left">No</td>
            <td align="left">c.161Tâ&gt;âC; p.Phe54Serâ+âc.161Tâ&gt;âC; p.Phe54Ser</td>
          </tr>
          <tr>
            <td align="left">III</td>
            <td align="left">M</td>
            <td align="left">31</td>
            <td align="left">16</td>
            <td align="left">1000â2000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Hypertrophy of calves, cramps and fatigability</td>
            <td align="left">Sparse rounded hypotrophic fibers and some splitting fibers</td>
            <td align="left">No</td>
            <td align="left">c.172Câ&gt;âT; p.Arg58Trpâ+âc.172Câ&gt;âT; p.Arg58Trp</td>
          </tr>
          <tr>
            <td align="left">IV,1</td>
            <td align="left">M</td>
            <td align="left">31</td>
            <td align="left">19</td>
            <td align="left">&gt;5000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Hyper-Ck-emia, still asymptomatic</td>
            <td align="left">NA</td>
            <td align="left">No</td>
            <td rowspan="2" align="left">c.1733Tâ&gt;âC; p.Phe578Serâ+âc.2272Câ&gt;âT; p.Arg758Cys</td>
          </tr>
          <tr>
            <td align="left">IV,2</td>
            <td align="left">F</td>
            <td align="left">20</td>
            <td align="left">15</td>
            <td align="left">1000â2000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Hyper-Ck-emia, still asymptomatic</td>
            <td align="left">NA</td>
            <td align="left">No</td>
          </tr>
          <tr>
            <td align="left">V</td>
            <td align="left">F</td>
            <td align="left">39</td>
            <td align="left">24</td>
            <td align="left">3000â4000</td>
            <td align="left">PQ short</td>
            <td align="left">Normal</td>
            <td align="left">Distal weakness arm, hyper-CK-emia, myalgia, painful contractures</td>
            <td align="left">Mitochondrial myopathy</td>
            <td align="left">No</td>
            <td align="left">c.1119â+â1 Gâ&gt;âA; p.Ser367IlefsX5â+âc.2272Câ&gt;âT; p.Arg758Cys</td>
          </tr>
          <tr>
            <td align="left">VI</td>
            <td align="left">F</td>
            <td align="left">44</td>
            <td align="left">39</td>
            <td align="left">3000â4000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Absence of weakness, mild calf hypotrophy</td>
            <td align="left">Central nuclei and increased fiber size</td>
            <td align="left">No</td>
            <td align="left">c.304â308 delAAAGA; p.Lys102ValfsX1â+âc.2102â2105 delATA; p.ÎAsn701</td>
          </tr>
          <tr>
            <td align="left">VII</td>
            <td align="left">M</td>
            <td align="left">46</td>
            <td align="left">17</td>
            <td align="left">3500â8000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Weakness of ankle dorsal and plantar flexors, hamstrings and adductors</td>
            <td align="left">Mild dystrophic changes</td>
            <td align="left">No</td>
            <td align="left">c.2498Tâ&gt;âA; p. Met833Lysâ+âc.2498Tâ&gt;âA; p. Met833Lys</td>
          </tr>
          <tr>
            <td align="left">VIII</td>
            <td align="left">M</td>
            <td align="left">75</td>
            <td align="left">37</td>
            <td align="left">500â2500</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Symmetric proximo-distal lower limb weakness, quadriceps and calf atrophy, abdominal and neck flexors muscles weakness and dysphonia</td>
            <td align="left">NA</td>
            <td align="left">No (walk with canes)</td>
            <td align="left">c.1639Câ&gt;âT; p.Arg547Xâ+âc.1639Câ&gt;âT; p.Arg547X</td>
          </tr>
          <tr>
            <td align="left">XVIII</td>
            <td align="left">F</td>
            <td align="left">57</td>
            <td align="left">30</td>
            <td align="left">1000</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia, lower quadriceps pain, possible congenital myopathy</td>
            <td align="left">Dystrophic changes</td>
            <td align="left">No (difficulties in deambulation)</td>
            <td align="left">c.616Aâ&gt;âG; p.Thr206Alaâ+âc.1211Gâ&gt;âT; p.Arg404Leu</td>
          </tr>
          <tr>
            <td align="left">IX,1</td>
            <td align="left">M</td>
            <td align="left">33</td>
            <td align="left">17</td>
            <td align="left">1600â8700</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Mild shoulder girdle weakness and atrophy, moderate scapular winging, mild pectoral muscle atrophy, mild facial weakness, global mildly decreased muscle mass limbs and trunk</td>
            <td align="left">Mild dystrophy, splitting fibers, slight increase in internal nuclei, slight type I fiber predominance</td>
            <td align="left">No</td>
            <td rowspan="2" align="left">c.191 dupA; p.Asn64LysfsX15â+âc.1733Tâ&gt;âC; p. Phe578Ser</td>
          </tr>
          <tr>
            <td align="left">IX,2</td>
            <td align="left">M</td>
            <td align="left">29</td>
            <td align="left">20</td>
            <td align="left">1000â2300</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Mild shoulder girdle weakness w/o atrophy or scapular winging, mild pectoral muscle atrophy, mild dorsal and volar forearm muscle atrophy and mild facial weakness</td>
            <td align="left">Moderate increase in fibers with central nuclei</td>
            <td align="left">No</td>
          </tr>
          <tr>
            <td align="left">X,1</td>
            <td align="left">M</td>
            <td align="left">47</td>
            <td align="left">28</td>
            <td align="left">&gt;3000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Hyper-Ck-emia, cramps, myalgia</td>
            <td align="left">Mild fiber size variability</td>
            <td align="left">No</td>
            <td rowspan="2" align="left">c.191 dupA; p.Asn64LysfsX15â+âc.2516Tâ&gt;âG; p.Met839Arg</td>
          </tr>
          <tr>
            <td align="left">X,2</td>
            <td align="left">F</td>
            <td align="left">50</td>
            <td align="left">NA</td>
            <td align="left">500â1500</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia, still asymptomatic</td>
            <td align="left">NA</td>
            <td align="left">No</td>
          </tr>
          <tr>
            <td align="left">XI</td>
            <td align="left">M</td>
            <td align="left">44</td>
            <td align="left">30</td>
            <td align="left">2200â3000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Progressive atrophy and weakness of biceps brachii muscles, hamstrings and hip adductors</td>
            <td align="left">Myopathic changes and necrotic fibers</td>
            <td align="left">No (difficulties in climbing stairs)</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.1261Câ&gt;âT; p.Gln421X</td>
          </tr>
          <tr>
            <td align="left">XII</td>
            <td align="left">M</td>
            <td align="left">71</td>
            <td align="left">32</td>
            <td align="left">2700â7800</td>
            <td align="left">Normal</td>
            <td align="left">FVCâ=â60%, lying: 50%, use of BIPap</td>
            <td align="left">Symmetric proximal UL and proximo-distal LL weakness with quadriceps and calf atrophy , abdominal and neck flexors muscles weakness and swallowing problems</td>
            <td align="left">Mild dystrophic changes</td>
            <td align="left">No (but sporadic use of wheelchair)</td>
            <td align="left">c.692Gâ&gt;âT; p.Gly231Valâ+âc.692Gâ&gt;âT; p.Gly231Val</td>
          </tr>
          <tr>
            <td align="left">XIII</td>
            <td align="left">M</td>
            <td align="left">38</td>
            <td align="left">32</td>
            <td align="left">1500â3000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">Diffuse myalgia, fatigability, absence of weakness and mild unilateral calf hypotrophy.</td>
            <td align="left">Minimal changes with increased fiber variability</td>
            <td align="left">No</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.191 dupA; p.Asn64LysfsX15</td>
          </tr>
          <tr>
            <td align="left">XIV,1</td>
            <td align="left">M</td>
            <td align="left">45</td>
            <td align="left">40</td>
            <td align="left">&gt;1000</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Myalgia and cramps</td>
            <td align="left">Mild dystrophic changes</td>
            <td align="left">No</td>
            <td rowspan="2" align="left">c.1627dupA; p.Met543Asn fsX10â+âc.1627dupA; p.Met543Asn fsX10</td>
          </tr>
          <tr>
            <td align="left">XIV,2</td>
            <td align="left">M</td>
            <td align="left">38</td>
            <td align="left">NA</td>
            <td align="left">&gt;1000</td>
            <td align="left">Normal</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia, still asymptomatic</td>
            <td align="left">NA</td>
            <td align="left">No</td>
          </tr>
          <tr>
            <td align="left">XIX</td>
            <td align="left">M</td>
            <td align="left">54</td>
            <td align="left">44</td>
            <td align="left">2000â3000</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">easy fatigability and difficulty walking</td>
            <td align="left">Dystrophic features with phagocytosed fibers</td>
            <td align="left">No</td>
            <td align="left">c.2235â+â1Gâ&gt;âA spl.â+âc.2235â+â1Gâ&gt;âA spl.</td>
          </tr>
          <tr>
            <td align="left">XX</td>
            <td align="left">M</td>
            <td align="left">42</td>
            <td align="left">15</td>
            <td align="left">4800â6600</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia; high-arched feet</td>
            <td align="left">Necrotizing myopathy</td>
            <td align="left">No</td>
            <td align="left">c.649-2Aâ&gt;âG spl.â+âc.649-2Aâ&gt;âG spl.</td>
          </tr>
          <tr>
            <td align="left">XXI</td>
            <td align="left">M</td>
            <td align="left">35</td>
            <td align="left">29</td>
            <td align="left">2830</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Hyper-Ck-emia</td>
            <td align="left">Slight dystrophy</td>
            <td align="left">No</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.1213Câ&gt;âT; p.Gln405X</td>
          </tr>
          <tr>
            <td align="left">XXIV</td>
            <td align="left">F</td>
            <td align="left">56</td>
            <td align="left">47</td>
            <td align="left">536</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">Autosomal dominant myopathy</td>
            <td align="left">Myopathic changes</td>
            <td align="left">NA</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.2387Câ&gt;âT; p.Ser796Leu</td>
          </tr>
          <tr>
            <td align="left">XLII</td>
            <td align="left">F</td>
            <td align="left">37</td>
            <td align="left">18</td>
            <td align="left">&gt;1000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">LGMD</td>
            <td align="left">Myopathic pattern</td>
            <td align="left">No</td>
            <td align="left">c.1207Câ&gt;âT; p.Gln403Xâ+âc.2411Câ&gt;âG; p.Cys804Ser</td>
          </tr>
          <tr>
            <td align="left">XLIII</td>
            <td align="left">F</td>
            <td align="left">23</td>
            <td align="left">13</td>
            <td align="left">&gt;1000</td>
            <td align="left">Normal</td>
            <td align="left">Normal</td>
            <td align="left">LGMD</td>
            <td align="left">Myopathic pattern</td>
            <td align="left">No</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.1520 delT p.Phe507SerfsX6</td>
          </tr>
          <tr>
            <td align="left">XLIV</td>
            <td align="left">F</td>
            <td align="left">33</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">LGMD</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">c.191 dupA; p.Asn64LysfsX15â+âc.191 dupA; p.Asn64LysfsX15</td>
          </tr>
          <tr>
            <td align="left">XLV</td>
            <td align="left">F</td>
            <td align="left">42</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">LGMD</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">c.692Gâ&gt;âT; p.Gly231Valâ+âc.2342Tâ&gt;âC; p.Leu781Pro</td>
          </tr>
          <tr>
            <td align="left">XLVI</td>
            <td align="left">M</td>
            <td align="left">39</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">c.1213Câ&gt;âT; p.Gln405Xâ+âc.2387Câ&gt;âT; p.Ser796Leu</td>
          </tr>
          <tr>
            <td align="left">XLVII</td>
            <td align="left">F</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">NA</td>
            <td align="left">c.729_730insT; p.Asn244Xâ+âc.2387Câ&gt;âT; p.Ser796Leu</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Patients XV, XVI and XVII have been described elsewhere (<xref rid="bib0085" ref-type="bibr">[16]</xref>) and are not included in the table. For patients XLIVâXLVII, detailed clinical data were not available.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>